Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.54 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | CASP9 | P55211 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 10/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | BMP1 | P13497 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29802241 | 0.94 | BACE1 (0.53) | GNPATENPEPBACE1BACE2CTSD | |
| SCHEMBL31634368 | 0.92 | KDM4E (0.51) | GNPATENPEPCASP1CASP3CASP7 | |
| SCHEMBL7166591 | 0.92 | GNPAT (0.48) | GNPATENPEPCASP1CASP3CASP7 | |
| SCHEMBL22310788 | 0.91 | GNPAT (0.47) | GNPATENPEPCASP1CASP3CASP7 | |
| SCHEMBL29630507 | 0.88 | ENPEP (0.56) | ENPEPCASP1CASP3CASP7CASP9 | |
| SCHEMBL17424544 | 0.87 | BACE1 (0.46) | GNPATENPEPCASP1CASP3CASP7 | |
| SCHEMBL29576249 | 0.87 | GNPAT (0.44) | GNPATENPEPCASP1CASP3CASP7 | |
| SCHEMBL29487532 | 0.87 | GNPAT (0.44) | GNPATENPEPCASP1CASP3CASP7 | |
| SCHEMBL7157952 | 0.87 | GNPAT (0.44) | GNPATENPEPCASP1CASP3CASP7 | |
| SCHEMBL29695567 | 0.87 | GNPAT (0.47) | GNPATENPEPBACE1CTSDBMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120192366-A | Tumor therapeutic molecule with curative effect self-amplification function | 东南大学 | 2025-06-24 | — | — | CN | claimed |
| US-20240272146-A1 | CHROMOGENIC AND FLUOROGENIC COMPOUNDS AND THEIR USE FOR BIOLOGICAL DETECTION | AAT BIOQUEST, INC. | 2024-08-15 | — | — | US | claimed |
| EP-1129108-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2002-01-09 | — | — | EP | claimed |
| EP-1129108-A1 | CASPASES AND APOPTOSIS | SmithKline Beecham Corporation (US) | 2001-09-05 | — | — | EP | claimed |
| WO-2000020440-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-04-13 | — | — | WO | claimed |
| US-20260102461-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | AIKIUM INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250387450-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | AIKIUM INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4646425-A1 | CASPASE-2 INHIBITOR COMPOUNDS | Kintsugi Therapeutics S.L. (ES) | 2025-11-12 | — | — | EP | disclosed |
| US-12419913-B2 | Modification of CAR-T cells | DNA TWOPOINTO, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250270255-A1 | CASPASE-2 INHIBITOR COMPOUNDS | KINTSUGI THERAPEUTICS S L (ES) | 2025-08-28 | — | — | US | disclosed |
| CN-120192366-A | Tumor therapeutic molecule with curative effect self-amplification function | 东南大学 | 2025-06-24 | — | — | CN | disclosed |
| CN-120192366-A | Tumor therapeutic molecule with curative effect self-amplification function | 东南大学 | 2025-06-24 | — | — | CN | disclosed |
| US-20140348753-A1 | HETEROCYCLE-FUNCTIONALIZED LUMINOGENS EXHIBITING AGGREGATION-INDUCED EMISSION | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2014-11-27 | — | — | US | disclosed |
| EP-0822983-A4 | APOPAIN | MERCK & CO INC (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1129108-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2002-01-09 | — | — | EP | disclosed |
| EP-1129108-A1 | CASPASES AND APOPTOSIS | SmithKline Beecham Corporation (US) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000020440-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-04-13 | — | — | WO | disclosed |
| US-5798442-A | Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases | MERCK FROSST CANADA, INC. (CA) | 1998-08-25 | — | — | US | disclosed |
| EP-0822983-A1 | APOPAIN | Merck & Co., Inc. (US) | 1998-02-11 | — | — | EP | disclosed |
| WO-1996033268-A1 | APOPAIN | MERCK & CO., INC. (US) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270255-A1 | CASPASE-2 INHIBITOR COMPOUNDS | CASP2, CASP1, CASP3 | GNPAT 3392/4885ENPEP 1030/4885CASP1 2/4885 |
| US-20250387450-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | SPPL2B, SPPL2A, CRYZ | GNPAT 3753/4885ENPEP 1159/4885CASP1 4109/4885 |
| US-20260102461-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | MAX, CRYZ, STAMBP | GNPAT 4335/4885ENPEP 1582/4885CASP1 2443/4885 |
| US-20140348753-A1 | HETEROCYCLE-FUNCTIONALIZED LUMINOGENS EXHIBITING AGGREGATION-INDUCED EMISSION | HSPE1, HAGH, LETM1 | GNPAT 3212/4885ENPEP 1840/4885CASP1 1736/4885 |
| US-20240272146-A1 | CHROMOGENIC AND FLUOROGENIC COMPOUNDS AND THEIR USE FOR BIOLOGICAL DETECTION | ANTXR2, CDYL, VIP | GNPAT 2886/4885ENPEP 42/4885CASP1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.